Studie CLARINET – průkaz antiproliferativního účinku lanreotidu

Czech version

Authors: B. Bencsiková
Authors‘ workplace: Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
Published in: Klin Onkol 2013; 26(6): 438-439
Category: Oncology Highlights

Sources

1. Vítek P, Strenková J, Sedláčková E et al. Registr neuroendokrinních nádorů (NET) v ČR po třech letech sběru dat. Klin Onkol 2013; 26(4): 271–280.

2. Niederle MB, Hackl M, Kaserer K et al. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumor Society classification: An analysis based on prospectively collected parametres. Endocr Relat Cancer 2010; 17(4): 909–918.

3. Yao JC, Hassan M, Phan A et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for NETS in 35,825 cases in the United States. J Clin Oncol 2008; 26(18): 3063–3072.

4. Rinke A, Müller HH, Schade-Brittinger C et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27(28): 4656–4663.

5. Caplin M, Ruszniewski P, Pavel M et al. A randomized, double-blind, placebo-Controlled study of Lanreotide Antiproliferative Response in patients with gastroenteropancreatic NeuroEndocrine Tumors (CLARINET). Eur J Cancer 2013; 49 (Suppl 3): LBA3.

6. Ipsen.com [homepage on the Internret]. Available from: http://www.ipsen.com/wp-content/uploads/2013/09/PR-Results-Clarinet-ESMO.pdf.